Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Apr 21;11(4):e7214.
doi: 10.1002/ccr3.7214. eCollection 2023 Apr.

Sclerosing epithelioid fibrosarcoma of the foot: A case report

Alex Mremi  1   2 , Adnan Sadiq  2   3 , Gregory Goodluck  4 , Jay Lodhia  2   4
Affiliations
Case Reports

Sclerosing epithelioid fibrosarcoma of the foot: A case report

Alex Mremi et al. Clin Case Rep. .

Abstract

Sclerosing epithelioid fibrosarcoma (SEF) is a rare and distinctive variant of fibrosarcoma. To date, about 100 cases only have been documented. Histopathologically, it resembles a variety of benign, pseudosarcomatous and other malignancies. Early diagnosis and treatment are vital for improving the treatment outcomes.

Keywords: Tanzania; case report; diagnosis; foot; sclerosing epithelioid fibrosarcoma.

PubMed Disclaimer

Conflict of interest statement

All authors have declared that no competing interests exist.

Figures

FIGURE 1
FIGURE 1
X‐ray of the foot showing a soft tissue mass associated with bone destruction (A); x‐ray of the affected leg highlighting focal cortical thickening left tibia (B); July 20, 2022.
FIGURE 2
FIGURE 2
Transtibial amputation demonstrating grossly circumscribed ulcerated mass of the foot measuring 15 × 13 cm (A); Cut section of the tumor highlighting a homogeneously white or white‐tan, lobulated tumor and very firm surface (B); August 3, 2022.
FIGURE 3
FIGURE 3
Photomicroscopy of SEF demonstrating densely sclerotic containing nests, strands and acini of small cells with scant clear cytoplasm; Hematoxylin and Eosin stained 200× original magnification (A); Aug 10, 2022. Immuno‐expression of tumor cells with Vimentin antibody; IHC 200× original magnification (B); August 3, 2022.
See this image and copyright information in PMC

References

    1. Chow LT, Lui YH, Kumta SM, Allen PW. Primary sclerosingepithelioidfibrosarcoma of the sacrum: a case report and review of the literature. J Clin Pathol. 2004;57(1):90‐94. - PMC - PubMed
    1. Folk GS, Williams SB, Foss RB, Fanburg‐Smith JC. Oral and maxillofacial sclerosingepithelioidfibrosarcoma: report of five cases. Head Neck Pathol. 2007;1(1):13‐20. doi:10.1007/s12105-007-0002-9 - DOI - PMC - PubMed
    1. Warmke LM, Meis JM. Sclerosing epithelioid fibrosarcoma: a distinct sarcoma with aggressive features. Am J Surg Pathol. 2021;45(3):317‐328. doi:10.1097/PAS.0000000000001559 - DOI - PubMed
    1. Ohlmann CH, Brecht IB, Junker K, et al. Sclerosingepithelioidfibrosarcoma of the kidney: clinicopathologic and molecular study of a rare neoplasm at a novel location. Ann Diagn Pathol. 2015;19(4):221‐225. doi:10.1016/j.anndiagpath.2015.04.005 - DOI - PubMed
    1. Doyle LA, Wang WL, Dal Cin P, et al. MUC4 is a sensitive and extremely useful marker for sclerosingepithelioidfibrosarcoma: association with FUS gene rearrangement. Am J Surg Pathol. 2012;36(10):1444‐1451. doi:10.1097/PAS.0b013e3182562bf8 - DOI - PubMed

Publication types

LinkOut - more resources